Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population Adults aged 50 and above with underlying medical...
PHILADELPHIA--(BUSINESS WIRE)-- #AREXVY--GSK’s RSV vaccine, AREXVY, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk ...
The FDA has granted Priority Review to oral ALK inhibitor Alecensa (alectinib) for patients with early-stage ALK-positive non-small cell lung cancer.
The FDA has granted Priority Review to Arexvy for the prevention of RSV disease in adults aged 50 to 59 years who are at increased risk for RSV disease.
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer